Cell therapy trial aims to halt vision loss in dry AMD

NCT ID NCT05626114

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The main goals are to see if the delivery works safely and if it can improve or preserve vision.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OpRegen (a retinal cell therapy)
What this could lead to: If successful, this could point toward a treatment that slows or stops vision loss from geographic atrophy.
What could go wrong: This is an early Phase IIa study with only 60 people, so results may not apply to everyone. The surgical delivery itself carries risks like infection or retinal damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEOGRAPHIC ATROPHY

Contacts and locations

Locations

Austin Clinical Research, LLC
RECRUITING

Austin, Texas, 78750-2298, United States
Cincinnati Eye Institute
RECRUITING

Blue Ash, Ohio, 45242-5537, United States
Duke Eye Center
RECRUITING

Durham, North Carolina, 27705-4699, United States
Hadassah MC
RECRUITING

Jerusalem, 9112001, Israel
Mid Atlantic Retina
RECRUITING

Philadelphia, Pennsylvania, 19107-5109, United States
Piedmont Eye Center
RECRUITING

Lynchburg, Virginia, 24502-4271, United States
Retina Consultants of Texas
RECRUITING

Bellaire, Texas, 77401, United States
Retina Vitreous Associates of Florida
RECRUITING

St. Petersburg, Florida, 33711-1141, United States
Retina-Vitreous Associates Medical Group
RECRUITING

Beverly Hills, California, 90211, United States
Retinal Consultants Medical Group
RECRUITING

Sacramento, California, 95825, United States
Sierra Eye Associates
RECRUITING

Reno, Nevada, 89502-1605, United States
Spokane Eye Clinical Research;Spokane Eye Surgery Center
RECRUITING

Spokane, Washington, 99204, United States
Tel Aviv Sourasky MC
RECRUITING

Tel Aviv, 6423906, Israel
Tennessee Retina PC
RECRUITING

Nashville, Tennessee, 37203-1513, United States
The Retina Care Center
RECRUITING

Baltimore, Maryland, 21209-2219, United States
The Retina Institute
RECRUITING

St Louis, Missouri, 63128-1729, United States
West Coast Retina
RECRUITING

San Francisco, California, 94109-5520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.